drug-candidate-discovery

To generate drug candidates for a specific protein target, you can use AI-powered molecule generation tools that retrieve target structures from PDB and UniProt, perform docking, and output evaluated druggable molecules as SDF files.

Starting structure-based drug design with only a disease name requires target identification through web databases, retrieving validated biological structures via UniProt and PDB integration, and then generating scaffolds for in silico evaluation.

Yes, RDKit can be used for in silico evaluation of generated molecule structures, working alongside structure retrieval and scaffold-based molecule generation to filter candidates by property criteria and produce 2D/3D visualizations.

Docking in AI-powered drug discovery works by evaluating generated drug-like molecules against retrieved target structures, defining binding pockets, and prioritizing candidates based on in silico evaluation results for structure-based optimization.

End-to-end drug candidate discovery tools output SDF files containing generated molecules, 2D/3D visualizations of the structures, and a comprehensive report detailing target identification, molecule generation, and in silico evaluation results.

Yes, you need web database access to identify targets for molecule generation, as the workflow relies on retrieving target information and integrating with PDB and UniProt to anchor discovery on validated biology before generating candidates.